AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15523321
Drug: Intermittent intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent intravenous low-dose dobutamine therapy
Trial: 9304358
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg i.v. 10 min before induction of anaesthesia (Group A)
Trial: 9304358
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg i.v. 10 min before end of surgery (Group B)
Trial: 9304358
Drug: Placebo at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo at both administration times (Group C)
Trial: 3820443
Drug: High-dose bismuth
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose bismuth subsalicylate (2 tablets, 262 mg each, four times daily)
Trial: 3820443
Drug: Low-dose bismuth
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose bismuth subsalicylate (1 tablet, 262 mg each, four times daily)
Trial: 3820443
Drug: Placebo (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (four times daily)
Trial: 27912106
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy (BLT); details on dosage and duration not available.
Trial: 9641189
Drug: Desferrioxamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desferrioxamine 0.5 mg/kg
Trial: 9641189
Drug: Desferrioxamine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desferrioxamine 2.5 mg/kg
Trial: 9641189
Drug: Desferrioxamine 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desferrioxamine 5.0 mg/kg
Trial: 2533803
Drug: Ethanol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.5 g/kg) + Diazepam (5 mg)
Trial: 2533803
Drug: Ethanol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.5 g/kg) + Meclophenoxate (100 mg)
Trial: 335940
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid added to wine (10 microgram/ml)
Trial: 31981604
Drug: 2.25% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.25% sodium hypochlorite gel
Trial: 26678525
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg hydroxycobalamin intramuscularly
Trial: 26678525
Drug: Sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection (placebo)
Trial: 18073464
Drug: Upper extremity
RxNorm normalized name: lymphedema garments, upper extremity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upper extremity treatment protocols involving EMG‐triggered neuromuscular stimulation and coupled bilateral movements
Trial: 17066490
Drug: Standard Treatment
RxNorm normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard Treatment plus Brief Feedback (BF)
Trial: 12615581
Drug: Aminophylline 250
RxNorm normalized name: aminophylline 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline 250 mg
Trial: 11444269
Drug: Acitretin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acitretin (20 mg/day, two 10 mg tablets daily)
Trial: 11444269
Drug: Control (tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (tablets without acitretin)
Trial: 9340174
Drug: Metoprolol (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (150 mg twice daily for 2 days)
Trial: 9340174
Drug: Verapamil (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (80 mg every 6 hours for 2 days)
Trial: 9340174
Drug: Untreated patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Untreated patients (drug free arm)
Trial: 1337423
Drug: L-648,051
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-648,051
Trial: 3510475
Drug: Oxacillin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxacillin (200 mg/kg/day by six bolus intravenous injections for 24 hours)
Trial: 29072372
Drug: Misoprostol treatment
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol treatment (800 μg vaginally)
Trial: 24423835
Drug: Hybrid intensity-modulated
RxNorm normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid intensity-modulated radiation therapy (IMRT) plan with flat beam open fields combined with nonflat beam IMRT fields (mixed DAO)
Trial: 23430163
Drug: Tapentadol (25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol (25, 50, and 75 mg)
Trial: 23430163
Drug: Tramadol (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (50, 100, and 150 mg)
Trial: 23430163
Drug: Hydromorphone (2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone (2, 4, and 6 mg)
Trial: 14557363
Drug: Small resistance
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small resistance arteries with M/L ratio greater than mean (0.098) or mean +2 SD (0.11)
Trial: 14557363
Drug: Small resistance
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small resistance arteries with M/L ratio less than mean (0.098) or mean +2 SD (0.11)
Trial: 14557363
Drug: M/L ratio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M/L ratio
Trial: 3813191
Drug: Uniphyl (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uniphyl (once daily at 8 P.M.)
Trial: 3813191
Drug: Theo-Dur (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theo-Dur (twice daily at 8 A.M. and 8 P.M.)
Trial: 24401049
Drug: Tight glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight glycemic control (target blood glucose range of 72 to 126 mg/dL)
Trial: 24401049
Drug: Conventional glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glycemic control (target blood glucose level below 216 mg/dL)
Trial: 18468933
Drug: Training programme
RxNorm normalized name: PUMP,LUTREPULSE PROGRAMMABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training programme (eight sessions, followed by training twice a week for 30‐45 minutes at home at the level of the ventilatory threshold [V(T)])
Trial: 18468933
Drug: Usual routine
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual routine treatment
Trial: 16428086
Drug: G. lucidum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G. lucidum polysaccharides at 5.4 g/day for 12 weeks
Trial: 14659379
Drug: Mimic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mimic therapy
Trial: 1688989
Drug: Diltiazem (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (60 mg three times a day for 3 days)
Trial: 31484031
Drug: In-home occupational
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In-home occupational therapy intervention (6 weeks)
Trial: 29220347
Drug: Community-wide treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-wide treatment (CWT)
Trial: 29220347
Drug: School-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based treatment (SBT)
Trial: 29220347
Drug: Two rounds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two rounds of treatment (with two intermittent or consecutive holiday years)
Trial: 29220347
Drug: Four rounds
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four rounds of treatment (CWT or SBT)
Trial: 26131911
Drug: cTACE with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cTACE with bevacizumab (5 mg/kg every 2 weeks for 52 weeks)
Trial: 23527952
Drug: hIVIG (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hIVIG (0.5 g/kg)
Trial: 23527952
Drug: VINC (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VINC (0.02 mg/kg)
Trial: 21751372
Drug: rhGH (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH (2 mg/day)
Trial: 16766489
Drug: Topical 2%
RxNorm normalized name: menthol topical 2% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2% niacinamide
Trial: 11270030
Drug: Propofol with
RxNorm normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol with ketamine (0.5 mg kg‐1)
Trial: 8342756
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 4 ml injected through the epidural needle before catheter passage
Trial: 3574424
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of isosorbide dinitrate (single dose)
Trial: 3574424
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of isosorbide dinitrate (twice daily)
Trial: 3574424
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of isosorbide dinitrate (three times daily)
Trial: 3574424
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of isosorbide dinitrate (four times daily)
Trial: 18512074
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant UFT (400 mg/day for 12 months)
Trial: 16809797
Drug: Ispronicline (TC-1734)
RxNorm normalized name: Ispronicline
DrugBank: Ispronicline (DB16205)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ispronicline (TC-1734) single-dose (2-320 mg)
Trial: 16809797
Drug: Ispronicline (TC-1734)
RxNorm normalized name: Ispronicline
DrugBank: Ispronicline (DB16205)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ispronicline (TC-1734) multiple-dose (50, 100, and 200 mg, once daily, x 10 days)
Trial: 14568795
Drug: 5% PVP-I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% PVP-I ear drops, administered topically, 3 drops 3 times daily for 10 days.
Trial: 14568795
Drug: 0.3% ciprofloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% ciprofloxacin ear drops, administered topically, 3 drops 3 times daily for 10 days.
Trial: 8740786
Drug: Chemotherapy-treated patients
RxNorm normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy-treated patients (excluding opposite-breast and skin tumors)
Trial: 8740786
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus Tamoxifen (excluding opposite-breast and skin tumors)
Trial: 1826883
Drug: Intravenous alpha-human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous alpha-human ANP (initial bolus of 0.5 micrograms/kg followed by a 21-min maintenance infusion at 0.05 micrograms.kg-1.min-1)
Trial: 1826883
Drug: Saline intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline intravenous infusion (control group)
Trial: 7040929
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 200 mg/m2 followed by 5-fluorouracil (5-FU) 600 mg/m2
Trial: 7040929
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 40 mg/m2 followed by 5-fluorouracil (5-FU) 600 mg/m2
Trial: 31350870
Drug: Topical insulin-liposomal
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical insulin-liposomal gel
Trial: 25044402
Drug: safinamide 50
RxNorm normalized name: safinamide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: safinamide 50 mg/d
Trial: 25044402
Drug: safinamide 100
RxNorm normalized name: safinamide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: safinamide 100 mg/d
Trial: 20576162
Drug: Conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drug treatment (intra-articular Sodium Hyaluronate injection)
Trial: 16117450
Drug: Autologous platelet
RxNorm normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous platelet gel (APG) application during cardiovascular surgery
Trial: 12125181
Drug: Plant-derived preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant-derived preparations for symptomatic treatment of obstipation, irritable bowel, and inflammatory bowel disease
Trial: 12125181
Drug: Phytotherapeutic preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytotherapeutic preparations
Trial: 9924589
Drug: Trivalent oral
RxNorm normalized name: poliovirus vaccine, live, trivalent oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent oral polio vaccine (TOPV) in Group A (vaccinated at 34-35 weeks)
Trial: 9924589
Drug: Trivalent oral
RxNorm normalized name: poliovirus vaccine, live, trivalent oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent oral polio vaccine (TOPV) in Group B (vaccinated at 38-40 weeks)
Trial: 3338259
Drug: 1‐[3H]noradrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1‐[3H]noradrenaline infusion
Trial: 12888589
Drug: Clarithromycin extended-release
RxNorm normalized name: Clarithromycin Extended-Release Tablets
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin extended-release formulation (1000 mg once daily for five consecutive days)
Trial: 9246981
Drug: Cefuroxime (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (1.5 g single injection)
Trial: 3101777
Drug: Adenosine (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (intravenous boluses)
Trial: 3101777
Drug: Aminophylline (antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (antagonist to adenosine)
Trial: 28089225
Drug: Individualised treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised treatment
Trial: 26267985
Drug: High-dose ergocalciferol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ergocalciferol (double dosage from K/DOQI recommendations)
Trial: 26267985
Drug: Conventional-dose ergocalciferol
RxNorm normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional-dose ergocalciferol (as recommended by K/DOQI guidelines)
Trial: 17280678
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (RSG) 8 mg/day
Trial: 9270631
Drug: Prolonged regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged regimen of prophylaxis with ticarcillin/clavulanate for 2 days and low-dose vancomycin until removal of the intraaortic balloon pump (n = 28)
Trial: 9270631
Drug: Prolonged regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged regimen of prophylaxis with ticarcillin/clavulanate and low-dose vancomycin (n = 28)
Trial: 8175538
Drug: Inhaled furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled furosemide (45 +/- 3 mg)
Trial: 8175538
Drug: Inhaled saline
RxNorm normalized name: Broncho Saline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled saline (S + HV)
Trial: 16517384
Drug: Augmented feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented feedback on specific biomechanical aspects of spinal manipulation therapy using an instrumented manikin
Trial: 12709737
Drug: Sirolimus (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (6 mg loading dose over 48 hours plus 2 mg/day maintenance) + low-dose cyclosporine (8 mg/kg/day)
Trial: 12709737
Drug: Sirolimus +
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus + low-dose cyclosporine
Trial: 1518121
Drug: Panipenem/betamipron (PAPM/BP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panipenem/betamipron (PAPM/BP) administered at 10 mg/10 mg/kg
Trial: 1518121
Drug: Panipenem/betamipron (PAPM/BP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panipenem/betamipron (PAPM/BP) administered at 20 mg/20 mg/kg
Trial: 1518121
Drug: Panipenem/betamipron (PAPM/BP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panipenem/betamipron (PAPM/BP) administered at 31.3 mg/31.3 mg/kg
Trial: 1518121
Drug: Panipenem/betamipron (PAPM/BP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panipenem/betamipron (PAPM/BP) administered in various doses (5.2 mg/5.2 mg to 31.3 mg/31.3 mg/kg)
Trial: 19033604
Drug: Tango dance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tango dance program (10 weeks, 40 hours, 2 hours twice a week)
Trial: 19033604
Drug: Walking program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walking program (10 weeks, 40 hours, 2 hours twice a week)
Trial: 7585841
Drug: ICI 204,636
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 204,636 (25 to 250 mg/d)
Trial: 2186067
Drug: Thermal biofeedback
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal biofeedback with adjunctive relaxation training (TBF)
Trial: 2186067
Drug: Thermal biofeedback
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal biofeedback plus cognitive therapy
Trial: 657994
Drug: Tinidazole (55.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole (55.5 mg/kg)
Trial: 657994
Drug: Metronidazole (52.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (52.0 mg/kg)
Trial: 31394314
Drug: Bouncing Image
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bouncing Image Training Task (BITT) - daily sessions for one week
Trial: 16939559
Drug: Sequential reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential reduction scenarios
Trial: 10960626
Drug: Estrogen 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen 0.625 mg/day
Trial: 6599665
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (continue medication)
Trial: 21090831
Drug: Rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20 mg once daily for a median follow-up of 1.9 years
Trial: 10575333
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 600 mg/day p.o. plus standard therapy
Trial: 1907675
Drug: 22.5% BCAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22.5% BCAA solution
Trial: 6125625
Drug: Beta-receptor blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-receptor blocker (10 mg of bunitrolol)
Trial: 28379623
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg once-daily aspirin
Trial: 28379623
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg twice-daily aspirin
Trial: 28379623
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg once-daily aspirin
Trial: 28379623
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg once-daily aspirin (control group)
Trial: 28027636
Drug: Nutrition education
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition education group sessions (12 weekly 75-min sessions)
Trial: 23273217
Drug: Multidisciplinary transmural
RxNorm normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Multidisciplinary transmural rehabilitation programme (duration: 2 to 6 months) consisting of neurorehabilitation treatment, empowerment training, and stroke education.
Trial: 31523022
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy during surgery
Trial: 23415472
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin 20 IU BID for 3 weeks
Trial: 23415472
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (in a small group of inpatients)
Trial: 17154160
Drug: Saforis (glutamine)
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saforis (glutamine) powder, 3 times/day during Treatment Cycle 1
Trial: 17154160
Drug: Placebo, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 3 times/day during Treatment Cycle 1
Trial: 15466766
Drug: Methotrexate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (10 mg) plus Prednisone (25 mg/d tapered to 0 mg/d within 24 weeks)
Trial: 15466766
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus Prednisone (25 mg/d tapered to 0 mg/d within 24 weeks)